Once-daily tapinarof cream 1% was associated with minimal, if any, systemic exposure in pediatric or adolescent patients with extensive atopic dermatitis, according to new findings from a maximal usage trial.1 In an abstract presented at the Maui Derm 2023 NP + PA Summer Conference in Colorado Springs this week, a team of US investigators reported a positive, safe...
